Widely Acclaimed | Study Results on Sheng Luo Lai® from Hansoh Pharma Published in eClinicalMedicine From World-Leading Lancet Journals
On October 28, eClinicalMedicine (IF:15.1), from top global medical journal group The Lancet, released its phase III clinical research paper on Sheng Luo Lai® (pegmolesatide injection), a class 1 innovative drug independently developed by Hansoh Pharma. The trials were led by Professor Jianghua Chen from the First Affiliated Hospital of Zhejiang University School of Medicine. It marks the first publication of clinical data on pegmolesatide in an international journal, fully demonstrating its efficacy and safety in the treatment of anemia in dialysis patients, and is also a testament to the quality of clinical research on innovative drugs originating in China reaching an advanced international standards.